$2M Debt Funding for Stromedix

Xconomy Boston — 

Stromedix, a Cambridge, MA-based developer of treatments for a cause of organ failure known as fibrosis, has raised $2 million of a prosposed $15.5 million round of debt financing, according to an SEC filing. The company, founded in 2007, has previously raised $29.4 million from investors including Atlas Venture, Bessemer Venture Partners, Red Abbey Venture Partners, New Leaf Venture Partners, and Frazier Healthcare Ventures. The company’s CEO, Michael Gilman, said in an e-mail that he was not able to be interviewed about the new financing today.